Eisai and Biogen’s Alzheimer’s drug Leqembi (generic name lecanemab) was the first fully-FDA approved disease-modifying treatment for early-stage Alzheimer’s disease in United States history,…
Brain Talk, hosted by Being Patient founder Deborah Kan and journalist Mark Niu, digs into the topics that matter most to the Being Patient…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
On October 23nd, the UK’s drug regulation agency — UK Medicines and Healthcare products Regulatory Agency — approved Eli Lilly’s anti-amyloid drug Kisunla for…
This article is part of the Journey to Diagnosis series, produced by Being Patient with support provided by Eli Lilly. What would you do…
This article is part of the Diversity & Dementia series, produced by Being Patient with support provided by Eisai. Latino and Hispanic populations have…
RESCHEDULED: On Tuesday, October 8th at 10 a.m. PT/1 p.m. ET, Alzheimer’s advocate Myra Garcia joins Being Patient Live Talks to discuss her experience…
On August 22nd, the UK’s drug regulation agency — UK Medicines and Healthcare products Regulatory Agency — approved Eisai and Biogen’s anti-amyloid drug Leqembi…
Scientists in America have developed a nasal spray that can remove proteins in the brain associated with Alzheimer’s disease – at least, in mice….
Last week at the Alzheimer’s Association’s International Conference 2024, the world’s leading scientists, researchers, and clinicians gathered to discuss the latest discoveries and upcoming research…
Stressful life events, such as the death of a loved one or divorce, put a person at greater risk of developing dementia in later…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
In the past year, the FDA approved two landmark new Alzheimer’s drugs: monoclonal antibodies designed to attack the disease’s underlying pathology, as opposed to…
A new drug for Alzheimer’s was just this month approved by the FDA for use in the United States, in people in the earliest…